1683 related articles for article (PubMed ID: 8238183)
1. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
3. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
Norris LA; Bonnar J
Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
[TBL] [Abstract][Full Text] [Related]
4. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
5. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
6. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
[TBL] [Abstract][Full Text] [Related]
7. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
8. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
10. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
[TBL] [Abstract][Full Text] [Related]
11. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
12. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
13. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; Spitzer WO; MacRae KD; Bruppacher R
Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral contraceptive progestins on serum copper concentration.
Berg G; Kohlmeier L; Brenner H
Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
16. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
17. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
19. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
20. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
